Search | Clinical Trials Finder

Conditions: Malnutrition, Dysentery, Social Transmission of Health Behaviors
Interventions: exposure to vitamin use, exposure to water chlorination, high in-degree, nominated by random; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 15 Years and older
Enrollment: 5,773 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions: Travelan, Placebo; Biological · Other
Lead sponsor: Immuron Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Clostridium Difficile
Interventions: Stool specimen; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Clostridium Difficile Infection
Interventions: Fecal Microbiota Therapy (FMT), Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Shigellosis
Interventions: Flexyn2a, Placebo, Flexyn2a plus adjuvant; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Shigella
Interventions: CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a; Biological
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Diarrhea, HIV Infections
Interventions: Saccharomyces boulardii; Drug
Lead sponsor: Biocodex; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Shigella
Interventions: CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Groton, Connecticut

Conditions: Clostridium Difficile Infection
Interventions: VP20621, Placebo; Biological · Other
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 42
States / cities: Modesto, California • Palm Desert, California • Sacramento, California + 39 more

Conditions: Infectious Diarrhea
Interventions: Biofire Film Array Gastrointestinal Panel; Diagnostic Test
Lead sponsor: Andrew Meltzer; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Shigellosis, Bacillary Dysentery
Interventions: Shigella flexneri 2a InvaplexAR; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Covid19
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: Entero Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 7 more

Conditions: Shigella
Interventions: ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU; Biological · Other
Lead sponsor: Eveliqure Biotechnologies GmbH; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Moderate Clostridium Difficile Infection
Interventions: LFF571, Vancomycin (POC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more

Conditions: Enterotoxigenic E. Coli (ETEC) Infection
Interventions: ACE527 vaccine, Placebo vaccine; Biological
Lead sponsor: TD Vaccines A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Clostridium Difficile
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cholera
Interventions: iOWH032, Placebo, V. cholerae Challenge, Antibiotics; Drug · Other
Lead sponsor: PATH; Other
Eligibility: 18 Years to 44 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Clostridium Difficile Infection
Interventions: Ibezapolstat, Vancomycin; Drug
Lead sponsor: Acurx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 29
States / cities: Scottsdale, Arizona • Apple Valley, California • Camarillo, California + 21 more

Conditions: Escherichia Infection
Interventions: B7A (ETEC challenge strain), CssBA, dmLT, Placebo; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Nitazoxanide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diarrhea Infectious
Interventions: VENBETA6890, Placebo; Drug
Lead sponsor: Mark Klempner; Other
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Coronavirus Infection
Interventions: Chinese Herbal Medicine; Dietary Supplement
Lead sponsor: Center for Integrated Care; Other
Eligibility: 18 Years to 114 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Escherichia Coli Infection
Interventions: Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Silver Spring, Maryland

Search by objective public record fields.

Social Network Interventions in Rural Honduras

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics

Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a

Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb

Treatment of Patients With Human Immunodeficiency Virus (HIV)-Related Chronic Diarrhea With Saccharomyces Boulardii or Placebo: A Double Blind Trial

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

Film Array Gastrointestinal Panel Compared to Usual Care for ED Evaluation of Infectious Diarrhea

Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

ACE527 Safety and Immunogenicity Study

Probiotics for Clostridium Difficile Infection in Older Adults

Cholera Anti-Secretory Treatment Trial

ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea